Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced on Tuesday that it has signed a definitive agreement to invest in Switzerland-based Solvias AG.

Since its formation in 1999, Solvias has grown to serve a diverse base of more than 600 biotech, medical device, cosmetic and pharmaceutical companies as it has expanded its platform of testing and analytical services to support biopharmaceutical products and emerging cell and gene therapies. Water Street says that it is collaborating with the company's management team to build Solvias into a premier global pharmaceutical laboratory services business.

Peter Strothman, partner, Water Street, said, 'Solvias stands out for its deep expertise, outstanding quality of work and commitment to continuous innovation to support its clients with bringing new products to market. We're excited to collaborate with Karen Huebscher and her leadership team to continue expanding their platform. Working together, we will invest in organic initiatives and strategic acquisitions that will extend Solvias' capabilities into new and complementary areas and expand their geographic reach on a global scale.'